CSPC Pharmaceutical Group Limited — Earnings Release 2003

May 20, 2003

Listed Company Information

CHINA PHARMA<01093> - Results Announcement (Summary) China Pharmaceutical Group Limited announced on 20/5/2003: (stock code: 01093 ) Year end date: 31/12/2003 Currency: HKD Auditors' Report: N/A Review of Interim Report by: Auditors (Unaudited ) (Unaudited ) Last Current Corresponding Period Period from 1/1/2003 from 1/1/2002 to 31/3/2003 to 31/3/2002 Note ($ ) ($ ) Turnover : 635,896,000 341,009,000 Profit/(Loss) from Operations : 188,024,000 66,435,000 Finance cost : (7,102,000) (5,327,000) Share of Profit/(Loss) of Associates : N/A N/A Share of Profit/(Loss) of Jointly Controlled Entities : 1,346,000 1,792,000 Profit/(Loss) after Tax & MI : 153,827,000 52,598,000 % Change over Last Period : +192 % EPS/(LPS)-Basic (in dollars) : 0.1024 0.0424 -Diluted (in dollars) : 0.1004 0.0418 Extraordinary (ETD) Gain/(Loss) : N/A N/A Profit/(Loss) after ETD Items : 153,827,000 52,598,000 1st Quarterly Dividend : Nil N/A per Share (Specify if with other : N/A N/A options) B/C Dates for 1st Quarterly Dividend : N/A Payable Date : N/A B/C Dates for (-) General Meeting : N/A Other Distribution for : N/A Current Period B/C Dates for Other Distribution : N/A Remarks: 1. The accounting policies adopted in the preparation of the unaudited consolidated results for the three months ended March 31, 2003 are consistent with those adopted in the annual accounts for the year ended December 31, 2002 except that the Group has adopted for the first time the revised Hong Kong Statement of Standard Accounting Practice 12 "Income Taxes" issued by the Hong Kong Society of Accountants. The adoption of this revised standard had no material effect on the results for the current period. 2. The calculation of the basic and diluted earnings per share is based on the following data: Three months ended March 31, 2003 2002 Profit attributable to shareholders HK$153,827,000 HK$52,598,000 ============== ============= Weighted average number of ordinary shares for the purpose of basic earnings per share 1,502,212,661 1,240,447,279 Effect of dilutive potential ordinary shares in respect of share options 29,324,161 18,093,949 ______________ ______________ Weighted average number of ordinary shares for the purpose of diluted earnings per share 1,531,536,822 1,258,541,228 ============= =============